Homotypic and heterotypic immune responses to Omicron variant in immunocompromised patients in diverse clinical settings.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
04 08 2022
04 08 2022
Historique:
received:
21
04
2022
accepted:
22
07
2022
entrez:
4
8
2022
pubmed:
5
8
2022
medline:
9
8
2022
Statut:
epublish
Résumé
Immunocompromised patients are predisposed to severe COVID-19. Here we compare homotypic and heterotypic humoral and cellular immune responses to Omicron BA.1 in organ transplant patients across a diverse clinical spectrum. We perform variant-specific pseudovirus neutralization assays for D614G, and Omicron-BA.1, -BA.2, and Delta variants. We also measure poly-and monofunctional T-cell responses to BA.1 and ancestral SARS-CoV-2 peptide pools. We identify that partially or fully-vaccinated transplant recipients after infection with Omicron BA.1 have the greatest BA.1 neutralizing antibody and BA.1-specific polyfunctional CD4
Identifiants
pubmed: 35927279
doi: 10.1038/s41467-022-32235-x
pii: 10.1038/s41467-022-32235-x
pmc: PMC9352686
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Viral Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4489Informations de copyright
© 2022. The Author(s).
Références
Vaccines (Basel). 2021 Aug 06;9(8):
pubmed: 34451999
Transplantation. 2022 Jul 1;106(7):1440-1444
pubmed: 35417115
Am J Transplant. 2021 Aug;21(8):2709-2718
pubmed: 33484237
Nat Rev Immunol. 2008 Apr;8(4):247-58
pubmed: 18323851
N Engl J Med. 2022 Feb 10;386(6):599-601
pubmed: 35030645
Nat Commun. 2021 Mar 3;12(1):1405
pubmed: 33658502
N Engl J Med. 2021 Aug 5;385(6):562-566
pubmed: 34347959
Front Immunol. 2018 Feb 16;9:276
pubmed: 29503649
Ann Intern Med. 2021 Sep;174(9):1330-1332
pubmed: 34125572
Emerg Microbes Infect. 2020 Dec;9(1):2394-2403
pubmed: 33043818
Ann Intern Med. 2022 Feb;175(2):226-233
pubmed: 34807716
Sci Transl Med. 2022 Mar 16;14(636):eabl6141
pubmed: 35103481
Nat Immunol. 2022 Mar;23(3):380-385
pubmed: 35115679
N Engl J Med. 2020 Dec 24;383(26):2586-2588
pubmed: 33259154
N Engl J Med. 2021 Sep 23;385(13):1244-1246
pubmed: 34379917
Nat Immunol. 2022 Feb;23(2):186-193
pubmed: 35105982
J Immunother Cancer. 2021 Jun;9(6):
pubmed: 34117116
J Infect Dis. 2021 Dec 1;224(11):1849-1860
pubmed: 34739078
Am J Transplant. 2021 Dec;21(12):3980-3989
pubmed: 34347934
Am J Transplant. 2022 Aug;22(8):2089-2093
pubmed: 35266606
Transplantation. 2014 Apr 27;97(8):846-53
pubmed: 24366008
JCI Insight. 2020 Oct 2;5(19):
pubmed: 32870820
J Infect Dis. 2022 Apr 06;:
pubmed: 35385875
Antiviral Res. 2020 Nov;183:104938
pubmed: 32979400
Transpl Infect Dis. 2021 Aug;23(4):e13637
pubmed: 33993630
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
J Hepatol. 2022 Apr 19;:
pubmed: 35452692
N Engl J Med. 2022 Apr 21;386(16):1579-1580
pubmed: 35294809
Nature. 2022 Mar;603(7901):488-492
pubmed: 35102311
Am J Transplant. 2021 Jun;21(6):2246-2253
pubmed: 33565711
Transplantation. 2021 Oct 1;105(10):2175-2183
pubmed: 34149003
Sci Rep. 2020 Jun 22;10(1):10104
pubmed: 32572168
Clin Infect Dis. 2022 Feb 02;:
pubmed: 35134129